Addex Therapeutics 2025 Annual General Meeting Details Revealed

Author: Ryan Hughes Updated: 06-03-2025 01:16 AM

Overview of Addex Therapeutics’ Upcoming Annual General Meeting

Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a pioneering biopharmaceutical firm focused on developing innovative allosteric modulators for neurological disorders, is gearing up for its Annual General Meeting (AGM) in 2025. The meeting is scheduled for June 24, 2025, and will be hosted at the Campus Biotech in Geneva, with doors opening at 10:30 am CEST.

Key Agenda Items for the AGM

The AGM is set to address several significant items:

Approval of the Annual Report and Financial Statements for 2024
Consultative vote on the Compensation Report for the previous year
Discussion on the appropriation of results
Discharge of Board members and Executive Management
Re-elections within the Board, including the Chairman
Approval of compensation packages for Board members and Executive Management
Re-elections of members of the Compensation Committee
Appointment of Auditors and Independent Voting Rights Representative
Additional miscellaneous items

For detailed insights into the complete agenda, interested parties can visit the Annual General Meetings section of Addex's official website.

About Addex Therapeutics

Addex Therapeutics is a clinical-stage biopharmaceutical company at the forefront of developing new treatment options for neurological disorders. The company’s flagship drug candidate, dipraglurant, is an mGlu5 negative allosteric modulator (NAM) that is currently being evaluated for its potential in aiding recovery from brain injuries, including complications following strokes and traumatic injuries.

Their partners at Indivior have successfully completed essential studies for a GABAB PAM drug candidate aimed at treating substance use disorders. Furthermore, Addex is progressing with an independent GABAB PAM program specifically for chronic cough, showcasing its commitment to expanding therapeutic avenues.

In addition, the company has a 20% equity stake in Neurosterix LLC, which is advancing a range of allosteric modulator programs. These initiatives include M4 PAM for schizophrenia, mGlu7 NAM for mood disorders, and mGlu2 NAM for managing mild neurocognitive disorders. Notably, Addex’s shares are actively traded on both the SIX Swiss Exchange and the NASDAQ Capital Market under the symbol "ADXN".

Contact Information

For further inquiries, the following contacts are available:

Tim Dyer
Chief Executive Officer
Phone: +41 22 884 15 55
Email: PR@addextherapeutics.com

Mike Sinclair
Partner, Halsin Partners
Phone: +44 (0)7968 022075
Email: msinclair@halsin.com

Frequently Asked Questions

What is the date of the 2025 AGM for Addex Therapeutics?

The Annual General Meeting is scheduled for June 24, 2025.

Where will the AGM take place?

The AGM will be held at Campus Biotech in Geneva, Switzerland.

What key topics will be discussed at the AGM?

Key topics include approval of financial statements, election of Board members, and discussion of compensation for executives.

How is Addex Therapeutics innovating in drug development?

Addex is developing novel small molecule allosteric modulators targeting a range of neurological disorders.

How can I get in touch with Addex Therapeutics?

For inquiries, you can contact Tim Dyer or Mike Sinclair via email or phone as listed.

About The Author

Hello, my name is Ryan Hughes. I am a financial, economics, and stock market specialist committed to assisting people in negotiating the intricacies of the financial system. Having a great deal of experience and a thorough grasp of market dynamics and economic trends, my area of expertise is converting complex financial ideas into understandable, practical knowledge. By use of my articles and blog entries, I hope to give you the information and assurance you need to make wise financial choices.

I've had the honor of interacting with a wide range of readers as a writer for several financial blogs, from new investors to seasoned market participants. To enable you to reach your financial goals, I want to make finance, economics, and stock market trends understandable and approachable. I appreciate you traveling with me toward success and financial literacy.

Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.